Allogeneic hematopoietic stem cell transplantation for childhood aplastic anemia: prospective trial in China

Transfus Apher Sci. 2011 Feb;44(1):41-7. doi: 10.1016/j.transci.2010.12.007. Epub 2011 Jan 20.

Abstract

We aim to investigate the efficacy and safety of the treatment with fully matched allogeneic hematopoietic stem cell transplants for children with severe aplastic anemia (SAA) in the first prospective trial in China. Six SAA children received allogeneic hematopoietic stem cell transplantation combined with chemotherapy. Five patients had successful engraftment while the sixth child regained normal peripheral blood counts consistent with spontaneous autologous hematopoiesis. Mean duration of follow-up was 2.75 years, and survival was 83%(5/6). The results indicated that allogeneic hematopoietic stem cell transplantation is a good option for the treatment of children with severe aplastic anemia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anemia, Aplastic / drug therapy
  • Anemia, Aplastic / surgery*
  • Bone Marrow Transplantation* / adverse effects
  • Bone Marrow Transplantation* / methods
  • Bone Marrow Transplantation* / statistics & numerical data
  • Cell Survival
  • Child
  • Child, Preschool
  • China
  • Combined Modality Therapy
  • Cyclosporine / therapeutic use
  • Female
  • Filgrastim
  • Follow-Up Studies
  • Graft Survival
  • Graft vs Host Disease / prevention & control
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hematopoietic Stem Cell Mobilization
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Living Donors
  • Male
  • Methotrexate / therapeutic use
  • Myeloablative Agonists / therapeutic use
  • Peripheral Blood Stem Cell Transplantation* / adverse effects
  • Peripheral Blood Stem Cell Transplantation* / methods
  • Peripheral Blood Stem Cell Transplantation* / statistics & numerical data
  • Recombinant Proteins
  • Siblings
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Cyclosporine
  • Filgrastim
  • Methotrexate